Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 1.00 |
| ▸ | TNKS | O95271 | 1/20 | 0.78 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.78 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.78 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.78 |
| ▸ | PARP6 | Q2NL67 | 1/20 | 0.78 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.78 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.78 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.78 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.78 |
| ▸ | PARP8 | Q8N3A8 | 1/20 | 0.78 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.78 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.78 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.78 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.78 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.78 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.78 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28516633 | 0.96 | PARP1 (1.00) | PARP1PARP3 | |
| SCHEMBL19569971 | 0.95 | PARP1 (0.90) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL10091980 | 0.92 | PARP1 (1.00) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL19769966 | 0.91 | PARP1 (1.00) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL27776285 | 0.91 | PARP1 (0.87) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL30293115 | 0.91 | PARP1 (0.89) | PARP1PARP3 | |
| SCHEMBL17173536 | 0.90 | PARP1 (1.00) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL15204472 | 0.90 | PARP1 (0.86) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL24301572 | 0.90 | PARP1 (0.82) | PARP1TNKSADORA1CDK6PDE3A | |
| SCHEMBL23378211 | 0.90 | PARP1 (0.82) | PARP1TNKSADORA1CDK6PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103172619-B | 4-(substituted benzyl)-1 (2H)-phthalazone analog derivative and preparation method thereof, pharmaceutical composition and purposes | Qilu Pharmaceutical Co.,Ltd. (CN) | 2016-12-14 | — | — | CN | claimed |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| WO-2023201338-A1 | COMBINATION THERAPY COMPRISING A MAT2A INHIBITOR AND A PARP INHIBITOR | IDEAYA BIOSCIENCES, INC. (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2022129925-A1 | NOVEL BIFUNCTIONAL MOLECULES FOR TARGETED PROTEIN DEGRADATION | AMPHISTA THERAPEUTICS LIMITED (GB) | 2022-06-23 | — | — | WO | disclosed |
| WO-2021262548-A1 | A PLATFORM FOR SCREENING NAD+ BINDING PROTEINS IN A CELLULAR CONTEXT | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-12-30 | — | — | WO | disclosed |
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-11-19 | — | — | US | disclosed |
| WO-2019186135-A1 | RADIOLABELLED COMPOUND | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2019-10-03 | — | — | WO | disclosed |
| WO-2018038680-A1 | PROCESSES FOR PREPARING OLAPARIB | SCINOPHARM TAIWAN, LTD. (TW) | 2018-03-01 | — | — | WO | disclosed |
| CN-103172619-B | 4-(substituted benzyl)-1 (2H)-phthalazone analog derivative and preparation method thereof, pharmaceutical composition and purposes | Qilu Pharmaceutical Co.,Ltd. (CN) | 2016-12-14 | — | — | CN | disclosed |
| US-9168266-B2 | Hybrid diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-10-27 | — | — | US | disclosed |
| US-20140315865-A1 | HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2014-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360523-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NCOA1, NCOR1, NCOA3 | PARP1 1873/4885TNKS 2187/4885ADORA1 3196/4885 |
| US-20140315865-A1 | HYBRID DIAZENIUMDIOLATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHOD OF TREATING CANCER | PARP4, PARP14, PARP1 | PARP1 3/4885TNKS 128/4885ADORA1 529/4885 |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | PARP1 1873/4885TNKS 2187/4885ADORA1 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.